Transcranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease (TRANSFORM-AD)

NACompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

September 11, 2019

Primary Completion Date

January 15, 2022

Study Completion Date

April 15, 2022

Conditions
Alzheimer Disease
Interventions
DEVICE

transcranial alternating current stimulation

The alternating current is administered through medical grade conductive pads that are produced specifically for the Nexalin technology. The pads are places on the forehead and behind each ear, and are connected to the Nexalin device with thin cables. Intervention will be implemented with a tACS device with gamma-frequency (40 Hz) and a peak-to-peak amplitude of 15mA, 30 one-hour sessions in 3 weeks (21 days).

DEVICE

sham stimulation

Electrodes will also be put on patient's forehead and behind each ear. The sham stimulator has the exactly same appearance with the true stimulator. Participants and operators cannot determine whether the stimulator is true based on its appearance or patients' feelings. However, when the device is started, no current flows through the electrodes. Participants in this controlled group will also receive sham stimulations with 30 one-hour sessions in 21 days.

Trial Locations (1)

100053

Xuanwu Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Xuanwu Hospital, Beijing

OTHER

NCT03920826 - Transcranial Alternating Current Stimulation for Patients With Mild Alzheimer's Disease (TRANSFORM-AD) | Biotech Hunter | Biotech Hunter